Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01567891 · ClinicalTrials.gov registry record · Phase 1
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
A Phase 1 study, sponsored by Adaptimmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01567891 is a Phase 1 study that has completed, run by Adaptimmune. The registered enrollment target is 9 participants.
The verdict
NCT01567891, a Phase 1 study, has completed, sponsored by Adaptimmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study, will take a subject's "T cells" and "teach" them to be able to recognize and attack the ovarian cancer cells. This is done by putting in a gene or genetic material that will change how a subject's T cells work and hopefully get them to attack and kill ovarian cancer cells. These new T cells are called "engineered T cells" because the new gene is causing them to become directed toward the ovarian cancer cells rather than their usual targets. These are also called "gene-modified T cells". For subjects who have the HLA A2 tissue-type marker, the T cells would be engineered to recognize a substance called "NY-ESO-1". After putting this new gene in T cells (a procedure called "gene therapy") the investigators will grow the cells in the laboratory and give these cells back to subjects.
Interventions
- BIOLOGICAL NYESO-1c259 T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-07-09 |
| Est. Completion | 2017-06-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01567891
The ClinicalTrials.gov registry entry for NCT01567891 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adaptimmune, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NYESO-1c259 T cells is the first listed.
NCT01567891 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01567891 about?
NCT01567891 is a clinical study titled "CT Antigen TCR-redirected T Cells for Ovarian Cancer.". This study, will take a subject's "T cells" and "teach" them to be able to recognize and attack the ovarian cancer cells. This is done by putting in a gene or genetic material that will change how a subject's T cells work and hopefully get them to attack and kill ovarian cancer cells. These new T ce...
What is the current status of trial NCT01567891?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2013-07-09. Estimated completion is 2017-06-06.
What interventions are being tested in trial NCT01567891?
The interventions under investigation include: NYESO-1c259 T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01567891?
This trial is sponsored by Adaptimmune, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.